Scientific rigor in conducting clinical trials to prove safety and efficacy of our technology is foundational to Viveve. Large, multicenter, randomized, and blinded clinical trials conducted following U.S. and International regulatory agency requirements is Viveve’s tradition. Sound clinical studies provide evidence that demonstrates the effectiveness of a medical device to safely treat a specific medical condition. Viveve is continuing its commitment to robust science with initiation of its U.S. pivotal PURSUIT trial for improvement of stress urinary incontinence in women. Stress urinary incontinence is a condition that effects an estimated 25 – 30 million women worldwide.

Viveve has a strong, protected intellectual property portfolio of U.S. and International patents for its Cryogen-cooled Monopolar Radiofrequency (CMRF) dual energy technology platform and its use in vaginal tissue. Recently, a new U.S. Method Patent for Stress Urinary Incontinence was issued to further strengthen the Company’s IP portfolio.

The Viveve System is currently used by physicians and women’s healthcare practitioners in over 50 countries worldwide. In the United States, the Viveve System is approved for use in general surgical procedures for electrocoagulation and hemostasis. International regulatory approvals and clearances include its use for vaginal laxity and/or improvement of sexual function and/or improvement of stress urinary incontinence in women.